In January 2018, we announced the validation of a new model of atopic dermatitis in mice.  Now that we have 18 months' experience of using it, here's our feedback. Back in January 2018, we announced the validation of a new model of atopic dermatitis in mice using topical applications of 2,4-Dinitrochlorobenzene (DNCB) over a period of 5 weeks in Balb/c mice (Newsletter #1). This validation allowed us to show that the model reproduces the essential characteristics of human pathology, and in

The ETAP-Cell project continues to make progress as per the expected timeline. The whole team is delighted to announce that the in vitro laboratory is now fully equipped and already producing its first results! In late January, ETAP-Lab created ETAP-Cell, a new in vitro pharmacological service in the field of evaluating proteopathic neurodegenerative diseases using our unique know-how in the solubilization and stabilization of oligomeric proteins (AβO, αSO and TauO). Three weeks ago, we successfully produced our first batch of soluble Aβ

  Within the framework of the European project MEDILIGHT, the consortium selected ETAP-Lab to outsource a preclinical study aiming at evaluating the efficacy of a miniaturized smart system built up to improve wound healing by light stimulation Chronic wounds represent a significant burden to patients, healthcare professionals, and healthcare systems, affecting over 40 million patients and creating costs of approximately € 40 billion annually. The European project MEDILIGHT aims to develop a smart, wearable medical device that utilizes the

New ETAP-Lab studies on TEMISIS’ drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced psoriasis model. The output of these studies showed that TEM1657 brings remarkable effects on psoriasis: • Higher efficacy compared to the reference molecule • No side effects • Oral administration, which is new for the psoriasis treatment The French biotech company “Temesis”, subsidiary of Plant Advanced Technologies, recently published a new press release to announce these new promising preclinical results on psoriasis

ETAP-Lab supports Plant Advanced Technologies in the development of its TEM1657 compound for the treatment of psoriasis TEM1657 is a drug candidate discovered and optimized by Plant Advanced Technologies (PAT), a French Biotech company based in Vandœuvre-lès-Nancy. The preclinical studies perfomed with TEM1657 in Etap-Lab's model of psoriasis in mice have demonstrated a similar efficacy to that of corticosteroids, the current reference of the market, but without their undesirable side effects. The results have been presented for the first time at the BIO convention in San Diego (USA)

New atopic dermatitis mouse model for in vivo efficacy studies Atopic dermatitis is a chronic allergic disease of the skin characterized by pruritus and eczematous skin lesions. It affects about 10 million people in the world, leading to a significant reduction in quality of life, and its incidence is continuously increasing in westernized countries. The pathogenesis of atopic dermatitis is unknown, but the disease seems to be correlated with specific immune and inflammatory mechanisms and keratinocytes, which are the main